Nanocrystal dispersion of DK-I-56-1, a poorly soluble pyrazoloquinolinone positive modulator of α6 GABAA receptors: formulation approach toward improved in vivo performance.

[1]  H. Eroğlu,et al.  Evaluation of improved oral bioavailability of ritonavir nanosuspension , 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[2]  W. Sieghart,et al.  Trigeminal neuropathic pain development and maintenance in rats are suppressed by a positive modulator of α6 GABAA receptors , 2019, European journal of pain.

[3]  W. Sieghart,et al.  The α6 subunit-containing GABAA receptor: A novel drug target for inhibition of trigeminal activation , 2018, Neuropharmacology.

[4]  Eknath D. Ahire,et al.  Parenteral nanosuspensions: a brief review from solubility enhancement to more novel and specific applications , 2018, Acta pharmaceutica Sinica. B.

[5]  W. Sieghart,et al.  Cerebellar α6‐subunit‐containing GABAA receptors: a novel therapeutic target for disrupted prepulse inhibition in neuropsychiatric disorders , 2018, British journal of pharmacology.

[6]  W. Sieghart,et al.  Design and Synthesis of Novel Deuterated Ligands Functionally Selective for the γ-Aminobutyric Acid Type A Receptor (GABAAR) α6 Subtype with Improved Metabolic Stability and Enhanced Bioavailability. , 2018, Journal of medicinal chemistry.

[7]  Salvatore Marceddu,et al.  Nile red nanosuspensions as investigative model to study the follicular targeting of drug nanocrystals. , 2017, International journal of pharmaceutics.

[8]  S. Lee,et al.  Development Considerations for Nanocrystal Drug Products , 2017, The AAPS Journal.

[9]  Lulu Wang,et al.  Safety of nanosuspensions in drug delivery. , 2017, Nanomedicine : nanotechnology, biology, and medicine.

[10]  Sourav Bhattacharjee,et al.  DLS and zeta potential - What they are and what they are not? , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[11]  G. Boeck,et al.  Development of a nanosuspension for iv administration: From miniscale screening to a freeze dried formulation. , 2016, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[12]  V. Nekkanti,et al.  Insoluble drug delivery strategies: review of recent advances and business prospects , 2015, Acta pharmaceutica Sinica. B.

[13]  Mohamad Haitham Ayad.  Rational formulation strategy from drug discovery profiling to human proof of concept , 2015, Drug delivery.

[14]  Rainer H Müller,et al.  Effect of drug physico-chemical properties on the efficiency of top-down process and characterization of nanosuspension , 2015, Expert opinion on drug delivery.

[15]  Xing Tang,et al.  Investigation of a nanosuspension stabilized by Soluplus® to improve bioavailability. , 2014, International journal of pharmaceutics.

[16]  William Wei Lim Chin,et al.  A brief literature and patent review of nanosuspensions to a final drug product. , 2014, Journal of pharmaceutical sciences.

[17]  T. Rades,et al.  Refining stability and dissolution rate of amorphous drug formulations , 2014, Expert opinion on drug delivery.

[18]  Ying Zheng,et al.  Stability of nanosuspensions in drug delivery. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[19]  A. Lundqvist,et al.  Evaluation of exposure properties after injection of nanosuspensions and microsuspenions into the intraperitoneal space in rats , 2013, Drug development and industrial pharmacy.

[20]  Yong Xia,et al.  The Preparation and Evaluation of Water-Soluble SKLB610 Nanosuspensions with Improved Bioavailability , 2013, AAPS PharmSciTech.

[21]  Jin Han,et al.  Development and in vivo/in vitro evaluation of novel herpetrione nanosuspension. , 2013, International journal of pharmaceutics.

[22]  Indrajit Ghosh,et al.  Identifying the correlation between drug/stabilizer properties and critical quality attributes (CQAs) of nanosuspension formulation prepared by wet media milling technology. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[23]  Hywel D Williams,et al.  Strategies to Address Low Drug Solubility in Discovery and Development , 2013, Pharmacological Reviews.

[24]  Wei Wu,et al.  Enhanced dissolution and oral bioavailability of aripiprazole nanosuspensions prepared by nanoprecipitation/homogenization based on acid-base neutralization. , 2012, International journal of pharmaceutics.

[25]  Si-Shen Feng,et al.  Vitamin E TPGS as a molecular biomaterial for drug delivery. , 2012, Biomaterials.

[26]  P. Turner,et al.  Administration of substances to laboratory animals: routes of administration and factors to consider. , 2011, Journal of the American Association for Laboratory Animal Science : JAALAS.

[27]  Jian Zhang,et al.  Physical and chemical stability of drug nanoparticles. , 2011, Advanced drug delivery reviews.

[28]  Elaine Merisko-Liversidge,et al.  Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology. , 2011, Advanced drug delivery reviews.

[29]  Rainer H Müller,et al.  State of the art of nanocrystals--special features, production, nanotoxicology aspects and intracellular delivery. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[30]  Sanjay Garg,et al.  Evaluation of a crystalline nanosuspension: polymorphism, process induced transformation and in vivo studies. , 2011, International journal of pharmaceutics.

[31]  N. Blagden,et al.  Hydrocortisone nanosuspensions for ophthalmic delivery: A comparative study between microfluidic nanoprecipitation and wet milling. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[32]  Ranjita Shegokar,et al.  Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. , 2010, International journal of pharmaceutics.

[33]  Aiguo Li,et al.  Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer , 2010, Drug development and industrial pharmacy.

[34]  Rainer H Müller,et al.  Nanosuspensions: a promising formulation for the new phospholipase A2 inhibitor PX-18. , 2010, International journal of pharmaceutics.

[35]  Feng Liu,et al.  Understanding the structure and stability of paclitaxel nanocrystals. , 2010, International journal of pharmaceutics.

[36]  B. Roth,et al.  Novel positive allosteric modulators of GABAA receptors: Do subtle differences in activity at α1 plus α5 versus α2 plus α3 subunits account for dissimilarities in behavioral effects in rats? , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[37]  S. Baumgartner,et al.  Advantages of celecoxib nanosuspension formulation and transformation into tablets. , 2009, International journal of pharmaceutics.

[38]  Ludo Froyen,et al.  A screening study of surface stabilization during the production of drug nanocrystals. , 2009, Journal of pharmaceutical sciences.

[39]  Sanjay Garg,et al.  Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery. , 2009, International journal of pharmaceutics.

[40]  Patrick Augustijns,et al.  Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. , 2008, International journal of pharmaceutics.

[41]  W. Sieghart,et al.  PWZ-029, a compound with moderate inverse agonist functional selectivity at GABAA receptors containing α5 subunits, improves passive, but not active, avoidance learning in rats , 2008, Brain Research.

[42]  Glyn Taylor,et al.  The effects of pharmaceutical excipients on drug disposition. , 2007, Advanced drug delivery reviews.

[43]  Daxiang Cui,et al.  Study on interaction between gold nanorod and bovine serum albumin , 2007 .

[44]  B. Shekunov,et al.  Particle Size Analysis in Pharmaceutics: Principles, Methods and Applications , 2007, Pharmaceutical Research.

[45]  S. Bates,et al.  Analysis of Amorphous and Nanocrystalline Solids from Their X-Ray Diffraction Patterns , 2006, Pharmaceutical Research.

[46]  B. Guth,et al.  Effect of commonly used vehicles on gastrointestinal, renal, and liver function in rats. , 2006, Journal of pharmacological and toxicological methods.

[47]  D. Bokonjić,et al.  Benzodiazepine site inverse agonists and locomotor activity in rats: Bimodal and biphasic influence , 2006, Pharmacology Biochemistry and Behavior.

[48]  N. Rasenack,et al.  In vitro characterization of jet-milled and in-situ-micronized fluticasone-17-propionate. , 2003, International journal of pharmaceutics.

[49]  Alexander V Kabanov,et al.  Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[50]  J Verweij,et al.  Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. , 2001, European journal of cancer.

[51]  R. Müller,et al.  Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. , 2001, Advanced drug delivery reviews.

[52]  O. Badary,et al.  Effect of Cremophor EL on the pharmacokinetics, antitumor activity and toxicity of doxorubicin in mice , 1998, Anti-cancer drugs.

[53]  D. Kessel,et al.  Effects of Cremophor EL on distribution of Taxol to serum lipoproteins. , 1994, British Journal of Cancer.

[54]  F. Kadir,et al.  Release and absorption rates of intramuscularly and subcutaneously injected pharmaceuticals (II) , 1994 .

[55]  M. Shimono,et al.  Effect of , 2017 .

[56]  V. Claassen.  Neglected factors in pharmacology and neuroscience research , 1994 .